|
|
Blood, 4 June 2009, Vol. 113, No. 23, pp. 6011-6014.
Prepublished online as a Blood First Edition Paper on March 23, 2009; DOI 10.1182/blood-2008-12-195388.
Previous Article | Next Article 
Submitted December 29, 2008
Accepted March 1, 2009
Comparable survival between HIV positive and HIV negative non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation
Jose L. Diez-Martin*, Pascual Balsalobre, Alessandro Re, Mariagrazia Michieli, Jose M. Ribera, Carmen Canals, Eulogio Conde, Anne Rosselet, Ian Gabriel, Rosario Varela, Bernardino Allione, Kate Cwynarski, Philippe Genet, Ildefonso Espigado, Pierre Biron, Norbert Schmitz, Anne E. Hunter, Augustin Ferrant, Gaelle Guillerm, Mark Hentrich, Manuel Jurado, Pascual Fernandez, David Serrano, Giuseppe Rossi, and Anna Sureda
Hospital General Universitario Gregorio Maranon, Madrid, Spain
Spedali Civili, Brescia, Italy
Centro di Riferimento Oncologico IRCCS, Aviano, Italy
Institut Catala d'Oncologia-Hosp. Univ. German Trias i Pujol, Badalona, Spain
EBMT Lymphoma Working Party, Barcelona, Spain
Hosp. Univ. Marques de Valdecilla, Univ. de Cantabria, Santander, Spain
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Hammersmith Hospital, London, United Kingdom
Comp. Hosp. Univ. de A Coruna, A Coruna, Spain
H SS Antonio e Biagio, Alessandria, Italy
Royal Free Hospital, London, United Kingdom
Hopital Victor Dupouy, Argenteuil, France
Hosp. Univ. Virgen del Rocio, Sevilla, Spain
Centre Leon Berard, Lyon, France
AK St. Georg, Hamburg, Germany
Leicester Royal Infirmary, Leicester, United Kingdom
Cliniques Universitaires St. Luc, Brussels, Belgium
H Augustin-Morvan, Brest, France
Klinikum Harlaching, Munchen, Germany
Hosp. Univ. Virgen de las Nieves, Granada, Spain
Hosp. Gen. Alicante, Alicante, Spain
* Corresponding author; email: jdiez.hgugm{at}salud.madrid.org.
Autologous stem cell transplantation (ASCT) has been successfully used in HIV-related lymphoma (HIV-Ly) patients on HAART. We report the first comparative analysis between HIV-Ly and a matched cohort of HIV(-) lymphoma patients. This retrospective EBMT study included 53 patients (66% non-Hodgkin (NHL) and 34% Hodgkin lymphoma (HL)) within each cohort. Both groups were comparable except for the higher proportion of males, mixed cellularity-HL and patients receiving G-CSF prior to engraftment and a smaller proportion receiving TBI-based conditioning within the HIV-Ly cohort. Incidence of relapse, overall and progression-free survival were similar in both cohorts. A higher non-relapse mortality within the first year post-ASCT was observed in the HIV-Ly group (8% vs 2%), predominantly due to early bacterial infections, although this was not statistically significant and did not influence survival. Thus, within the HAART era HIV patients should be considered for ASCT according to the same criteria adopted for HIV(-) lymphoma patients.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. Hentrich, X. Schiel, A. Niedermeier, L. Lutz, R. Rupec, C. Stief, J. Bogner, M. Karthaus, and A. Gerl
Successful salvage high-dose chemotherapy and autologous stem-cell transplantation in HIV-related germ-cell tumor
Ann. Onc.,
November 1, 2009;
20(11):
1900 - 1901.
[Full Text]
[PDF]
|
 |
|
|
|